Key result
Heterozygous VKORC1 mutation links to severe warfarin resistance requiring over daily for PE.
Why the study?
The authors present a case of warfarin resistance to discuss underlying genetic polymorphisms.
Case Report (n=1)
This case highlights warfarin resistance, where a patient required more than 15 mg daily to achieve a therapeutic INR, likely due to genetic polymorphisms.
Answers are grounded in this paper and cite their sources.
May prompt pharmacogenetic consideration in refractory cases; extends VKORC1 associations but remains hypothesis-generating.
Warfarin is the most widely prescribed anticoagulant in the world. Patients who need more than 15 mg per day should be considered warfarin-resistant. Nearly 30 genes have been reported in association with warfarin pharmacogenetics but genetic polymorphisms in the genes encoding CYP2C9 and VKORC1 have been shown to act as the most important determinants of drug dosage requirements. The major enzyme responsible for the metabolism of S-warfarin, the more potent of warfarin's two stereoisomers, is CYP2C9. Warfarin inhibits vitamin K epoxide reductase (VKOR). A 30-year-old woman was referred to our clinic for pulmonary embolism. She was treated with low molecular weight heparin. The warfarin dose was titrated up to 15 mg daily but after one week, the INR (international normalized ratio) was still subtherapeutic level at 1.8. In this paper, we discuss underlying genetic polymorphisms about warfarin resistance.
No takes yet. Share an insight, caveat, or question.
Gönlügür et al. (2019) conducted a case report in Pulmonary embolism and warfarin resistance (n=1). Warfarin was evaluated on INR (international normalized ratio). A 30-year-old woman with pulmonary embolism exhibited warfarin resistance with a subtherapeutic INR of 1.8 despite receiving of warfarin daily, with genetic testing revealing a heterozygous VKORC1 -1639>A mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: